Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1–infected individuals …
DE Nixon, RJ Bosch, ES Chan, NT Funderburg… - Journal of clinical …, 2017 - Elsevier
Background Persistent immune activation and inflammation in virologically suppressed
human immunodeficiency virus (HIV) infection are linked to excess cardiovascular risk.
Objective To evaluate atorvastatin as a strategy to reduce cardiovascular risk. Methods
A5275 was a multicenter, prospective, randomized, double-blind, placebo-controlled, cross-
over pilot study of atorvastatin (10 mg/day for 4 weeks then 20 mg/day for 16 weeks) with a
planned enrollment of 97 HIV-infected participants≥ 18 years old, receiving boosted …
human immunodeficiency virus (HIV) infection are linked to excess cardiovascular risk.
Objective To evaluate atorvastatin as a strategy to reduce cardiovascular risk. Methods
A5275 was a multicenter, prospective, randomized, double-blind, placebo-controlled, cross-
over pilot study of atorvastatin (10 mg/day for 4 weeks then 20 mg/day for 16 weeks) with a
planned enrollment of 97 HIV-infected participants≥ 18 years old, receiving boosted …